Tomasson: Elranatamab is a bispecific antibody that binds to the BCMA on the tumor cells and the CD3-positive bone marrow ...

Antivirals such as nirmatrelvir/ritonavir (Paxlovid), remdesivir (Veklury), and molnupiravir (Lagevrio) remain approved or ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

Panelist discusses how the MonumenTAL-1 study led to the approval of talquetamab in patients with 4 or more prior lines of ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

DelveInsight's Hematology Market Insights report provides the current and forecast market analysis, individual leading ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb ...

Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...